Archive for the ‘Biothrax’ Category

Emergent Revises Upward 2010 Financial Forecast

Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]

August 3, 2010  Tags: , , , , , , ,   Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax

ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]

July 15, 2010  Tags: , , , , ,   Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri  No Comments

Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments

ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) led by CEO Fuad El-Hibri,announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations.  The company’s international sales efforts have resulted in these sales [...]

July 7, 2010  Tags: , , , , ,   Posted in: Anthrax vaccines, Biothrax, El-Hibri, Emergent BioSolutions, Vaccine., fuad el-hibri  No Comments